Search results

Technology foresight or technology futures analysis is increasingly being recognised as a tool for planning sustainable development. Similarly, as argued by many, biotechnology could be harnessed for sustainable development. Hence, the purpose of this paper is to map out foresight activities in the Indian biotechnology innovation system.

The present paper has adopted a systemic approach to analyse the foresight activities in the Indian biotechnology sector. An online Delphi survey, including interviews, was conducted for 750 biotech units.

The greatest need of foresight is felt in the biopharma sector, especially in the small- and medium-sized firms. The methodologies used are only pre-foresight in nature and for short-term time horizons. The output preferred is “setting the R&D planning and priorities”. “Assessing socioeconomic and environment impact” is not accorded a high priority. Most of the regulatory agencies do not carry out foresight exercises.

The research holds significance for evolving sustainable development policy.

Strong evidence has shown that increased agricultural productivity and opened international trade are required to maintain and enhance food security. The multilateral trading system has been unable to keep trade open for one subset of agricultural products – those that use biotechnology in production. This chapter assesses whether preferential trade agreements can represent potential alternative sources of trade rules for dealing with trade in the products of biotechnology. This chapter analyzes and compares three case studies of preferential trade agreements (Canada-EU Comprehensive Economic and Trade Agreement, EU-US Transatlantic Trade and Investment Partnership, and Trans-Pacific Partnership), by focusing on negotiations pertaining to products of biotechnology. The three preferential trade agreements have shown little inventiveness in their attempts to put in place rules of trade for the products of modern agricultural biotechnology and have established forums where only issues can be discussed. They are forums to talk and talk without any means to force closure on negotiations. Given the inability to deal with the issue of biotechnology at the WTO or other multilateral forums, the recent and current negotiations of major preferential agreements represent the second best alternative which still needs to be analyzed and still needs to be understood by policy makers, academics, and the population at large. This chapter represents a first step in that direction.

Researchers continue to seek understanding of industrialization as a state managed process. How to create and implement new industries based on advanced knowledge is on the policy agenda of many advanced nations. Measures that promote these developments include national capacity building in science and technology, the formation of technology transfer systems, and the establishment of industrial clusters. What these templates often overlook is an analysis of use. This chapter aims to increase the understanding of the processes that embed new solutions in structures from an industrial network perspective. The chapter describes an empirical study of high-technology industrialization in Taiwan that the researcher conducts to this end. The study shows that the Taiwanese industrial model is oversimplified and omits several important factors in the development of new industries. This study bases its findings on the notions that resource combination occurs in different time and space, the new always builds on existing resource structures, and the users are important as active participants in development processes.

Biotechnology is now considered a key emerging sector in Ireland's economic landscape. Defined as the ‘application of scientific and engineering principles to the processing of materials by biological agents’ (Forfás Report, 2005), biotechnology is now the main high-technology driver affecting industries as diverse as food, agriculture human health and environmental protection. In 2002 it was estimated that over 400,000 people worldwide were employed in biotech (InterTradeIreland, 2002), with the market for biotechnology products worth an estimated 100 billion (European Commission, 2002). However, according to the Technology Foresight Ireland Report (1999), these figures are predicted to increase significantly, with the expectation that, by the end of 2006, the biotechnology sector will be worth an estimated 250 billion and will employ more than three million workers.

This chapter examines the role of “continuations” (procedural revisions of patent applications) within software patents and overall patenting in the United States during 1987–1999. Our research represents the first effort of which we are aware to analyse data on continuations in software or any other patent class, and as such provides information on the effects of 1995 changes in the U.S. patent law intended to curb “submarine patenting.” Our analysis of all U.S. patents issued 1987–1999 shows that the use of continuations grew steadily in overall U.S. patenting through 1995, with particularly rapid growth in continuations in software patenting. Sharp reversals in these growth rates after 1995 suggest that changes in the U.S. patent law were effective. Continuations were used more intensively by packaged-software firms prior to the effective date of the 1995 changes in patent law than by other patentees, and both software and non-software patents subject to continuation tend to be more valuable.

This research explored the literature regarding successful leadership practices and how these practices form the organizational context that leads to success in the biotechnology industry. Dominate themes emerged in general leadership strategies, leading research and development scientists, moving ideas from research to the consumer and the culture of research versus practice. Themes include leaders must be adaptable and able to lead effectively in a dynamic environment. Leaders need to consistently articulate the vision throughout the organization. Leaders need to be strategic decision-makers and flexible enough to allow the vision to adjust to the culture and the environment. Leaders need to communicate effectively and create an organization where communication flows efficiently at all levels. Leaders need to recognize clear cultural differences between functional groups, and they need to empower employees at all levels to make strategic decisions. Leaders need to know which decisions must be retained as his or her sole responsibility.

Inter-organizational alliances and the networks they generate have been a central topic in organization theory over the last decade. However, network analyses per se have been static. Even when information over time has been available, the temporal component has been set aside or aggregated to the end point of the study. Substantially more research has been conducted on organizations initiating inter-organizational relationships. The organization-level research has been decidedly dynamic in nature. However, organization-level research has largely examined the structural characteristics of the networks generated by organizational actions. Work combining network-level and organization-level phenomena has been rare and, to our knowledge, no research including the effects of organization-level actions on the evolution of network-level phenomena has occurred.

In this chapter we use more than 6000 R&D alliances and more than 6500 M&D alliances initiated by more than 1000 biotech firms in the U.S. over a 30 year period to construct quarterly networks. We test 13 hypotheses linking the actions of the firms to changes in network structure. Utilizing hazard-rate models we test the effects of institutional status, positional status (centrality), and structural status (coreness) of firms on their propensity to form ties with different structural consequences. Our research indicates that both R&D and M&D networks in U.S. biotechnology are developing a distinct core/periphery structure over time. Furthermore, we find support for a process of preferential attachment wherein organizations are more likely to form ties with organizations of similar institutional and structural status. Furthermore, we find evidence for cross effects, for example attachment processes that enfold across the two networks.

By taking conventionalist view of the evolution of biotechnology, we suggest that the process by which entrepreneurs determined what made biotechnology valuable and figured out how to organize around such an economic logic was contested. The shape that biotechnology has ultimately taken emerged from the resolution of these contests. Convention theory – as elaborated in Boltanski and Thévenot's (2006) On Justification ¹ – argues that our economy is shaped by participants affecting the rules of economic action. Whereas most economists would argue that the assignment of value underpins any system of exchange, conventionalists suggest that this value is not only given by the principles of optimization but instead can be derived from many possible spheres such as civic duty, attainment of fame, proof of technologic performance, and demonstration of creativity. More specifically, Boltanski and Thévenot (2006, p. 43) claim that the establishment of a particular logic “comes about as a part of a coordinated process that relies on two supports: a common identification of market goods, whose exchange defines the course of action, and a common evaluation of these objects in terms of prices that make it possible to adjust various actions.” Simply put, economic logics embody principles of economic coordination or conventions that guide interpretation of the technology and its value.

An emerging stream of literature has observed that project-based organizations rely increasingly on a network of collaborations originating from the ongoing process of creating and dissolving relationships that bring new project opportunities. Project-based networks are widespread in knowledge-intensive and creative industries, such as life-science and biotechnology, nanotechnology, and software, film, and music industry. This chapter examines the structural characteristics of project-based network-ties in German biotech. We focus on the consequences of local versus international network ties for the innovative success of German biotechnology firms. The findings of our longitudinal event history analysis indicate that the most valuable learning drivers are international research alliances and centrality within the international research network. Surprisingly, we do not find any local effects: neither the density of a local research cluster, nor its diversity or age is of significance. Our results shed new light on the relevance of international linkages for firms that are engaged in project-based learning networks.

The burgeoning interest over the last decade in technology transfer at universities in the United States has driven contentious debates over patent policy. In this context, biotech patenting has become the poster-child for claims that the proliferation of patenting by universities, and in the private sector, is undermining scientific norms and threatening innovation. Commentators have expressed particular fears about the negative effects of biotech patenting on the public information commons and concerns about emerging “patent anticommons.” This chapter argues that the standard (finite) commons model is being misapplied in the biotech arena because, owing to the complexity of biological processes and the power of existing biotech methods to produce genetic data, biomedical science is, in crucial respects, an unbounded, uncongested common resource. These findings imply that strategic biotech patenting of problem-specific research tools (i.e., single-nucleotide polymorphisms, drug targets) is not economically justified and therefore is irrational.